Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tharimmune ( (THAR) ) has shared an announcement.
On August 4, 2025, Tharimmune, Inc. appointed Nancy Davis, a renowned philanthropist and founder of Race to Erase MS and Cure Addiction Now, to its Board of Directors. Davis, known for her patient advocacy and strategic fundraising, is expected to bring valuable insights to Tharimmune’s mission of developing innovative therapies, including its lead product TH104, which targets the effects of weaponized fentanyl and the opioid crisis. Her appointment is seen as a strategic move to enhance the company’s efforts in addressing critical unmet medical needs.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates in the fields of immunology, inflammation, and oncology. Its lead clinical asset, TH104, is being developed to address respiratory and nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids. The company also explores treatments for chronic pruritus and autoimmune diseases, leveraging its proprietary EpiClick Technology for targeting solid tumors.
Average Trading Volume: 38,992
Technical Sentiment Signal: Sell
Current Market Cap: $5.66M
Learn more about THAR stock on TipRanks’ Stock Analysis page.